help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on February 22, 2007
Endocrinology, doi:10.1210/en.2006-1355
A more recent version of this article appeared on May 1, 2007
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
148/5/2181    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Habibi, J.
Right arrow Articles by Sowers, J. R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Habibi, J.
Right arrow Articles by Sowers, J. R
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

Submitted on October 4, 2006
Accepted on February 1, 2007

Rosuvastatin, a HMG-CoA Reductase Inhibitor, Decreases Cardiac Oxidative Stress and Remodeling in Ren2 Transgenic Rats

Javad Habibi PhD, Adam Whaley-Connell DO, MSPH, Mahnaz A. Qazi MD, Melvin R Hayden MD, Shawna A Cooper MS, Anthony Tramontano MD, John Thyfault PhD, Craig Stump MD, PhD, Carlos Ferrario MD, Ranganath Muniyappa MD, PhD, and James R Sowers MD*

University of Missouri School of Medicine, Diabetes and Cardiovascular Lab, and Harry S Truman VA Medical Center, Wake Forest University School of Medicine, SUNY Stony Brook School of Medicine at Winthrop-University Hospital, and The New York Harbor VA Health Care System, Brooklyn Campus, NY, University of Arizona, and Arizona VA Medical Center, Tucson, AZ

* To whom correspondence should be addressed. E-mail: sowersj{at}deptofmed.arizona.edu.

Angiotensin-II (Ang-II)-stimulated increases in NADPH oxidase activity and oxidative stress are known to play a key role in cardiac remodeling. Inhibition of isoprenylation and activation of small G proteins, such as Rac1, a component of NADPH oxidase, may mediate the anti-oxidant actions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins). In this study, we investigated the effects of rosuvastatin on cardiac oxidative stress and remodeling in transgenic rats (Ren2) overexpressing the mouse renin gene with elevated cardiac levels of Ang-II. We treated 6-7-week old Ren2 rats and age-matched Sprague-Dawley (SD) rats with rosuvastatin (10mg/kg/day) or vehicle for three weeks. At the end of the treatment period, left-ventricular mass, wall thickness, ejection fraction (by echocardiography) and cardiac remodeling (by light microscopy and immunohistochemistry) were assessed. In addition, myocardial content of nitrotyrosine, malondialdehyde (MDA), NADPH-oxidase subunits (gp91phox, p40phox, and p22phox) and Rac1 were analyzed by immunochemistry. Systolic blood pressure (SBP) was significantly higher in Ren2 compared to SD rats (p<0.05); rosuvastatin had no significant effect on SBP in either group. In Ren2, but not SD rats, rosuvastatin significantly improved the ventricular ejection fraction, cardiac hypertrophy and perivascular fibrosis (p<0.05). In addition, rosuvastatin administration significantly decreased the accentuated myocardial gp91phox, p40phox, p22phox, and Rac1 expression. These changes were accompanied by a parallel reduction in myocardial lipid peroxidation (nitrotyrosine and MDA content) (p<0.05). These results suggest that in vivo statin treatment through its direct actions on the heart reduces oxidative stress and remodeling including ventricular mass regression in the Ang-II-dependent Ren2 model.


Key words: Statin • Transgenic Ren2 rat • Cardiac remodeling • Angiotensin II • NADPH oxidase




This article has been cited by other articles:


Home page
EndocrinologyHome page
J. Habibi, A. Whaley-Connell, M. R. Hayden, V. G. DeMarco, R. Schneider, S. D. Sowers, P. Karuparthi, C. M. Ferrario, and J. R. Sowers
Renin Inhibition Attenuates Insulin Resistance, Oxidative Stress, and Pancreatic Remodeling in the Transgenic Ren2 Rat
Endocrinology, November 1, 2008; 149(11): 5643 - 5653.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Whaley-Connell, J. Habibi, S. A. Cooper, V. G. DeMarco, M. R. Hayden, C. S. Stump, D. Link, C. M. Ferrario, and J. R. Sowers
Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat
Am J Physiol Endocrinol Metab, July 1, 2008; 295(1): E103 - E109.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. Whaley-Connell, J. Habibi, R. Nistala, S. A. Cooper, P. R. Karuparthi, M. R. Hayden, N. Rehmer, V. G. DeMarco, B. T. Andresen, Y. Wei, et al.
Attenuation of NADPH Oxidase Activation and Glomerular Filtration Barrier Remodeling With Statin Treatment
Hypertension, February 1, 2008; 51(2): 474 - 480.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. Ramasubbu, J. Estep, D. L. White, A. Deswal, and D. L. Mann
Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy.
J. Am. Coll. Cardiol., January 29, 2008; 51(4): 415 - 426.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. Yagi, K.-i. Aihara, Y. Ikeda, Y. Sumitomo, S. Yoshida, T. Ise, T. Iwase, K. Ishikawa, H. Azuma, M. Akaike, et al.
Pitavastatin, an HMG-CoA Reductase Inhibitor, Exerts eNOS-Independent Protective Actions Against Angiotensin II Induced Cardiovascular Remodeling and Renal Insufficiency
Circ. Res., January 4, 2008; 102(1): 68 - 76.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
G.-X. Zhang, X.-M. Lu, S. Kimura, and A. Nishiyama
Role of mitochondria in angiotensin II-induced reactive oxygen species and mitogen-activated protein kinase activation
Cardiovasc Res, November 1, 2007; 76(2): 204 - 212.
[Abstract] [Full Text] [PDF]


Home page
Therapeutic Advances in Cardiovascular DiseaseHome page
L. Romayne Kurukulasuriya, G. Athappan, G. Saab, A. Whaley Connell, and J. R. Sowers
Review: HMG CoA reductase inhibitors and renoprotection: the weight of the evidence
Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 49 - 59.
[Abstract] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. A. Cooper, A. Whaley-Connell, J. Habibi, Y. Wei, G. Lastra, C. Manrique, S. Stas, and J. R. Sowers
Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance
Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2009 - H2023.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
E. M. Redout, M. J. Wagner, M. J. Zuidwijk, C. Boer, R. J.P. Musters, C. van Hardeveld, W. J. Paulus, and W. S. Simonides
Right-ventricular failure is associated with increased mitochondrial complex II activity and production of reactive oxygen species
Cardiovasc Res, September 1, 2007; 75(4): 770 - 781.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Whaley-Connell, G. Govindarajan, J. Habibi, M. R. Hayden, S. A. Cooper, Y. Wei, L. Ma, M. Qazi, D. Link, P. R. Karuparthi, et al.
Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat
Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E355 - E363.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society